Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can new tracers make many cancers light up on scans?

NCT ID NCT04147494

Diagnosis Sponsor: Jonsson Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 21, 2026 · Last updated Aug 21, 2026

Summary

This early-phase trial explores whether two experimental PET/CT tracers, 68Ga-FAPI-46 and 68Ga-PSMA-11, can accurately highlight various non-prostate cancers, including breast, lung, and pancreatic tumors. Participants scheduled for surgery will receive the tracers before their scans, and the images will be compared with the removed tumor tissue to see if the tracers truly mark cancer cells. The study aims to determine where these tracers accumulate in the body and whether they could offer a new imaging tool for diagnosing and guiding treatment of these cancers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Two experimental PET imaging tracers, gallium Ga 68 FAPI-46 and gallium Ga 68-labeled PSMA-11, given intravenously before a PET/CT scan.
What this could lead to
If successful, these tracers could provide a new way to visualize a wide range of cancers, potentially improving detection and surgical planning.
What could go wrong
This is a very early, small exploratory study. The tracers may not accumulate consistently across all cancer types, and results may not translate to routine clinical use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

29 people

The number who actually took part.

Started

Nov 2019

Expected to finish

Oct 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with the following cancer types: * Breast cancer * Colon cancer * Esophageal cancer * Gastric cancer * Head and Neck cancer * Lung cancer * Ovarian cancer * Pancreatic cancer * Renal cancer * Uterus cancer * Patients who are scheduled to undergo surgical resection of the primary tumor and/or metastasis * Patient can provide written informed consent * Patient is capable of complying with study procedures * Patient is able to remain still for duration of imaging procedure (up to one hour) Exclusion Criteria: * Patient is pregnant or nursing * Patients with any new cancer therapy between the baseline 18F-FDG PET/CT and the investigational FAPI PET/CT * Patient has underlying disease which, based on the judgment of the investigator, might interfere with the collection of high quality data

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm carcinoma of esophagus colon carcinoma colonic neoplasm esophageal cancer Esophageal Neoplasms exocrine pancreatic carcinoma gastric cancer gastric carcinoma gastric neoplasm head and neck cancer head and neck carcinoma lung cancer lung carcinoma lung neoplasm malignant pancreatic neoplasm neoplasm ovarian cancer ovarian carcinoma pancreatic adenocarcinoma pancreatic neoplasm renal carcinoma renal cell carcinoma uterine cancer uterine corpus cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast carcinoma Colon carcinoma Esophageal carcinoma Gastric carcinoma Head and neck carcinoma Kidney carcinoma Lung carcinoma Ovarian carcinoma Pancreatic carcinoma Solid neoplasm Uterine corpus cancer

Contacts and locations

Locations

  • Ethan Lam

    Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.